Random, Open-label Multicenter, Phase IV Study Assessing the Safety and Efficacy of Two Regimens of Ranibizumab 0.5 mg in Chinese Patients With Neovascular AMD

Trial Profile

Random, Open-label Multicenter, Phase IV Study Assessing the Safety and Efficacy of Two Regimens of Ranibizumab 0.5 mg in Chinese Patients With Neovascular AMD

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 27 Apr 2017

At a glance

  • Drugs Ranibizumab (Primary)
  • Indications Age-related macular degeneration
  • Focus Therapeutic Use
  • Acronyms ARTIS
  • Most Recent Events

    • 03 Nov 2016 Primary end point has been changed from Number of participants with treatment-related adverse events to Mean Snellen BCVA at every visit, hence trial focus also change.
    • 03 Nov 2016 Planned End Date changed from 1 Dec 2016 to 1 Jan 2017.
    • 05 Jul 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top